Rohan Palanki

Rohan Palanki

Auto-generated profile, based on publicly available information

Rohan Palanki

Department of Bioengineering, University of Pennsylvania

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2024 in Nano Letters
Verified
Journal Article
Closed access
EHEmily L. Han
Emily L. Han
STSophia Tang
Sophia Tang
DKDongyoon Kim
Dongyoon Kim
AMAmanda M. Murray
Amanda M. Murray
KSKelsey L. Swingle
Kelsey L. Swingle
MMMichael Mitchell
Michael Mitchell

12 April 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
BLBrian P. Landry
Brian P. Landry
RPRohan Palanki
Rohan Palanki
NDNikola Dyulgyarov
Nikola Dyulgyarov
LHLucas A. Hartsough
Lucas A. Hartsough
JTJeffrey J. Tabor
Jeffrey J. Tabor
Two-component systems (TCSs) are the largest family of multi-step signal transduction pathways in biology, and a major source of sensors for biotechnology. However, the input concentrations to which biosensors respond are often mismatched with application requirements. Here, we utilize a mathematical model to show that TCS detection thresholds increase with the phosphatase activity of the sensor histidine kinase. We experimentally validate this result in engineered Bacillus subtilis nitrate and E. coli aspartate TCS sensors by tuning their detection threshold up to two orders of magnitude. We go on to apply our TCS tuning method to recently described tetrathionate and thiosulfate sensors by mutating a widely conserved residue previously shown to impact phosphatase activity. Finally, we apply TCS tuning to engineer B. subtilis to sense and report a wide range of fertilizer concentrations in soil. This work will enable the engineering of tailor-made biosensors for diverse synthetic biology applications.

17 July 2023 in ACS Nano
Verified
Journal Article
Closed access
RPRohan Palanki
Rohan Palanki
SBSourav K. Bose
Sourav K. Bose
ADApeksha Dave
Apeksha Dave
BWBrandon M. White
Brandon M. White
CBCara Berkowitz
Cara Berkowitz
WPWilliam H. Peranteau
William H. Peranteau

23 January 2024 in Nano Letters
Verified
Journal Article
Closed access
EHEmily L. Han
Emily L. Han
MPMarshall S. Padilla
Marshall S. Padilla
RPRohan Palanki
Rohan Palanki
DKDongyoon Kim
Dongyoon Kim
KMKaitlin Mrksich
Kaitlin Mrksich
MMMichael Mitchell
Michael Mitchell

1 July 2015 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
SASumit Arora
Sumit Arora
NTNikhil Tyagi
Nikhil Tyagi
ABArun Bhardwaj
Arun Bhardwaj
LRLilia Rusu
Lilia Rusu
RPRohan Palanki
Rohan Palanki
Seema SinghSeema Singh
Seema Singh

30 July 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
RPRohan Palanki
Rohan Palanki
JRJohn S. Riley
John S. Riley
SBSourav K. Bose
Sourav K. Bose
VLValerie Luks
Valerie Luks
ADApeksha Dave
Apeksha Dave
WPWilliam H. Peranteau
William H. Peranteau
Monogenic blood diseases are among the most common genetic disorders worldwide. These diseases result in significant pediatric and adult morbidity, and some can result in death prior to birth. Novel ex vivo hematopoietic stem cell (HSC) gene editing therapies hold tremendous promise to alter the therapeutic landscape but are not without potential limitations. In vivo gene editing therapies offer a potentially safer and more accessible treatment for these diseases but are hindered by a lack of delivery vectors targeting HSCs, which reside in the difficult-to-access bone marrow niche. Here, we propose that this biological barrier can be overcome by taking advantage of HSC residence in the easily accessible liver during fetal development. To facilitate the delivery of gene editing cargo to fetal HSCs, we developed an ionizable lipid nanoparticle (LNP) platform targeting the CD45 receptor on the surface of HSCs. After validating that targeted LNPs improved messenger ribonucleic acid (mRNA) delivery to hematopoietic lineage cells via a CD45-specific mechanism in vitro, we demonstrated that this platform mediated safe, potent, and long-term gene modulation of HSCs in vivo in multiple mouse models. We further optimized this LNP platform in vitro to encapsulate and deliver CRISPR-based nucleic acid cargos. Finally, we showed that optimized and targeted LNPs enhanced gene editing at a proof-of-concept locus in fetal HSCs after a single in utero intravenous injection. By targeting HSCs in vivo during fetal development, our Systematically optimized Targeted Editing Machinery (STEM) LNPs may provide a translatable strategy to treat monogenic blood diseases before birth.